Literature DB >> 7579400

Ectopic expression of rhombotin-2 causes selective expansion of CD4-CD8- lymphocytes in the thymus and T-cell tumors in transgenic mice.

G A Neale1, J E Rehg, R M Goorha.   

Abstract

Although the proto-oncogene rhombotin-2 (RBTN-2) is widely expressed in most tissues, it is not expressed in T cells. We investigated the potential for overexpression of RBTN-2 to cause tumors in T cells and other tissues by constructing transgenic mice that expressed RBTN-2 under control of the metallothionein-1 promoter. Despite overexpression of RBTN-2 in all tissues, transgenic mice developed T-cell tumors only, thus indicating that tumorigenesis caused by RBTN-2 is T-cell-specific. Thymic tumors were found between 37 and 71 weeks and were invariably associated with metastasis to nonlymphoid organs. Thymuses from apparently healthy transgenic mice were also examined. In some mice there was an 10-fold increase in the CD4-CD8- thymocyte subset, yet the total number of thymocytes was the same as that in wild-type mice. Thymic homeostasis was maintained by a compensatory reduction in the CD4+CD8+ subset. The expansion of CD4-CD8- thymocytes was associated with increased expression of RBTN-2 and with increased cell proliferation. No differences were found in the proportion of thymocytes undergoing apoptosis in transgenic mice. Furthermore, RBTN-2-induced expansion of CD4-CD8- cells did not block differentiation of these cells. Thymuses with 30% CD4-CD8- cells were essentially monoclonal, indicating that all thymic immunophenotypes were derived from a single clone. Overall, our data are consistent with the following scenario: (1) RBTN-2 expression in T cells causes selective and polyclonal proliferation of CD4-CD8- thymocytes accompanied by a compensatory decrease in other thymocyte subsets; (2) a clone with growth advantage and differentiation potential is selected and populates the thymus; and (3) this clone eventually breaches homeostasis of the thymus, accompanied or followed by metastasis to other organs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579400

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  MN1-TEL myeloid oncoprotein expressed in multipotent progenitors perturbs both myeloid and lymphoid growth and causes T-lymphoid tumors in mice.

Authors:  Hiroyuki Kawagoe; Gerard C Grosveld
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

2.  Solution structure of a tethered Lmo2(LIM2) /Ldb1(LID) complex.

Authors:  Siavoush Dastmalchi; Lorna Wilkinson-White; Ann H Kwan; Roland Gamsjaeger; Joel P Mackay; Jacqueline M Matthews
Journal:  Protein Sci       Date:  2012-09-25       Impact factor: 6.725

3.  Identification and characterization of LMO4, an LMO gene with a novel pattern of expression during embryogenesis.

Authors:  D A Kenny; L W Jurata; Y Saga; G N Gill
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

4.  Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.

Authors:  Louise M Treanor; Emmanuel J Volanakis; Sheng Zhou; Taihe Lu; Charles J Sherr; Brian P Sorrentino
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

5.  Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice.

Authors:  D S Chervinsky; X F Zhao; D H Lam; M Ellsworth; K W Gross; P D Aplan
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

6.  Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer.

Authors:  Eleanor Y M Sum; Davendra Segara; Belinda Duscio; Mary L Bath; Andrew S Field; Robert L Sutherland; Geoffrey J Lindeman; Jane E Visvader
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-16       Impact factor: 11.205

7.  The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells.

Authors:  G G Grütz; K Bucher; I Lavenir; T Larson; R Larson; T H Rabbitts
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

8.  Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.

Authors:  Alex Appert; Chang-Hoon Nam; Natividad Lobato; Eva Priego; Ricardo Nunez Miguel; Tom Blundell; Lesley Drynan; Helen Sewell; Tomoyuki Tanaka; Terence Rabbitts
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

9.  Gene expression profiling of precursor T-cell lymphoblastic leukemia/lymphoma identifies oncogenic pathways that are potential therapeutic targets.

Authors:  Y-W Lin; P D Aplan
Journal:  Leukemia       Date:  2007-04-12       Impact factor: 11.528

10.  The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.

Authors:  Matthew P McCormack; Alan Forster; Lesley Drynan; Richard Pannell; Terence H Rabbitts
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.